ライフサイエンスコーパス: attention deficit

1 with the body, suggesting a more generalized attention deficit.

2 attery assessed both spatial and non-spatial attention deficits.

3 d provided the anatomical basis for kinds of attention deficits.

4 e) produced a systematic exaggeration of the attention deficits.

5 riance for motor and language than memory or attention deficits.

6 ameters are neural markers of musicality and attention deficits.

7 diminished thalamic gain control can lead to attention deficits.

8 isability (ID), and frequently presents with attention deficits.

9 ntial that durably improves resistant visual attention deficits after brain injury.

10 creased in prefrontal cortex of rats showing attention deficits after developmental malnutrition.

11 Attention deficit and hyperactivity disorder (ADHD) is o

12 gical disorders, including schizophrenia and attention deficit and hyperactivity disorder (ADHD).

13 including Christianson syndrome, autism, and attention deficit and hyperactivity disorder.

14 , the overall group demonstrated significant attention deficits and a significantly greater frequency

15 Any correlation between motor and attention deficits and between functional connectivity i

16 Attention deficits and cognitive performance were evalua

17 TRN-restricted deletion of Ptchd1 leads to attention deficits and hyperactivity, both of which are

18 1DS have high prevalence of autism spectrum, attention deficit, and anxiety disorders, as well as psy

19 T) levels, hyperactivity, working memory and attention deficits, and impulsive-like behavior.

20 d with daytime consequences such as fatigue, attention deficits, and mood instability.

21 Here, we show that motor and attention deficits are selectively associated with abnor

22 ies suggested that Chrna7 deficient mice had attention deficits, but were normal in baseline behavior

23 cancers and inflammatory bowel disorder, to attention deficit disorder and childhood obesity.

24 teria were systematic childhood diagnosis of attention-deficit disorder, ADHD, or a research diagnost

25 However, these various forms of attention deficits generally have abnormal microstructur

26 disorders, like autism spectrum disorders or attention-deficit hyper-activity disorders, which are kn

27 irst-line treatment of choice in adults with attention-deficit hyperactive disorder (ADHD) and some s

28 They also had higher rates of attention deficit hyperactivity disorder (30.7% compared

29 g been recognized that many individuals with attention deficit hyperactivity disorder (ADHD) also hav

30 Neurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD) and auti

31 son's disease (PD) as well as treatments for attention deficit hyperactivity disorder (ADHD) and depr

32 ociated with autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD) and schi

33 and to neuropsychiatric disorders including attention deficit hyperactivity disorder (ADHD) and schi

34 or (GRM) GFIN, previously observed to impact attention deficit hyperactivity disorder (ADHD) and schi

35 number of psychiatric conditions, including attention deficit hyperactivity disorder (ADHD) and subs

36 Parkinsonism and attention deficit hyperactivity disorder (ADHD) are wide

37 esses tied to the adult outcome of childhood attention deficit hyperactivity disorder (ADHD) could gu

38 Attention deficit hyperactivity disorder (ADHD) has been

39 Attention deficit hyperactivity disorder (ADHD) is a chi

40 Attention deficit hyperactivity disorder (ADHD) is a com

41 Attention deficit hyperactivity disorder (ADHD) is a com

42 Attention deficit hyperactivity disorder (ADHD) is a neu

43 Attention deficit hyperactivity disorder (ADHD) is assoc

44 d treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD) is uncle

45 Impulsivity and inattention related to attention deficit hyperactivity disorder (ADHD) may incr

46 olescents and young adults without childhood attention deficit hyperactivity disorder (ADHD) often pr

47 This study examined the effects of childhood attention deficit hyperactivity disorder (ADHD) symptoms

48 tism, bipolar disorder, major depression and attention deficit hyperactivity disorder (ADHD) using ge

49 Attention deficit hyperactivity disorder (ADHD) was the

50 speech impairment, variable expressivity of attention deficit hyperactivity disorder (ADHD), and mot

51 ed executive inhibition is a core deficit of attention deficit hyperactivity disorder (ADHD), which i

52 moderate the effect of stress on severity of attention deficit hyperactivity disorder (ADHD), with st

53 s to excess mortality among individuals with attention deficit hyperactivity disorder (ADHD), yet ass

54 4, and illustrate a use case of HaploReg for attention deficit hyperactivity disorder (ADHD)-associat

55 me, obsessive-compulsive disorder (OCD), and attention deficit hyperactivity disorder (ADHD).

56 ted in multiple psychopathologies, including attention deficit hyperactivity disorder (ADHD).

57 to numerous psychiatric disorders including attention deficit hyperactivity disorder (ADHD).

58 ated with neuropsychiatric disorders such as attention deficit hyperactivity disorder (ADHD).

59 omy have been tied to the clinical course of attention deficit hyperactivity disorder (ADHD).

60 on is a key executive function impairment in attention deficit hyperactivity disorder (ADHD).

61 n proposed as an important endophenotype for attention deficit hyperactivity disorder (ADHD).

62 many neuropsychiatric conditions, including attention deficit hyperactivity disorder (ADHD).

63 al brain regions in children and adults with attention deficit hyperactivity disorder (ADHD).

64 st widely used animal model for the study of attention deficit hyperactivity disorder (ADHD).

65 Neurodevelopmental disorders (NDDs) (attention deficit hyperactivity disorder [ADHD], autism

66 (mood and anxiety), behavioral disturbance (attention deficit hyperactivity disorder and conduct dis

67 ase guanfacine is approved for children with attention deficit hyperactivity disorder but not well st

68 he study of monozygotic twins discordant for attention deficit hyperactivity disorder can elucidate m

69 ited understanding of why many children with attention deficit hyperactivity disorder do not outgrow

70 on between the persistence and remittance of attention deficit hyperactivity disorder may provide a f

71 ed with neurotransmitter dysregulation, e.g. attention deficit hyperactivity disorder or Alzheimer's

72 We show medicalisation in attention deficit hyperactivity disorder to be a complex

73 0.05 and P </= 0.01) with schizophrenia and attention deficit hyperactivity disorder were also nomin

74 ers, including excessive daytime sleepiness, attention deficit hyperactivity disorder, Alzheimer dise

75 bsessive-compulsive disorder and behaviours, attention deficit hyperactivity disorder, and autistic s

76 adolescent psychopathology, such as anxiety, attention deficit hyperactivity disorder, and substance

77 sease, schizophrenia, autism, depression and attention deficit hyperactivity disorder, as well as age

78 ur candidates under clinical development for attention deficit hyperactivity disorder, binge eating d

79 sensory gating, and social behavior and that attention deficit hyperactivity disorder, bipolar disord

80 lycerides, type 2 diabetes, waist-hip ratio, attention deficit hyperactivity disorder, bipolar disord

81 but high variability in patients with autism/attention deficit hyperactivity disorder, compared with

82 We examine the contemporary debate on attention deficit hyperactivity disorder, in which conce

83 eneral anesthesia exposure early in life and attention deficit hyperactivity disorder, language proce

84 nge of neuropsychiatric illnesses, including attention deficit hyperactivity disorder, mood disorders

85 lphenidate (MPH), a first-line treatment for attention deficit hyperactivity disorder, on D2/3 recept

86 a clinical measure of attention--symptoms of attention deficit hyperactivity disorder--from resting-s

87 ents, but lower variability in patients with attention deficit hyperactivity disorder.

88 rupted in many psychiatric disorders such as attention deficit hyperactivity disorder.

89 n associated with schizophrenia, autism, and attention deficit hyperactivity disorder.

90 ognitive symptoms of Alzheimer's disease and attention deficit hyperactivity disorder.

91 orable metabolic profile and a lower risk of attention deficit hyperactivity disorder.

92 ecreased susceptibility to schizophrenia and attention deficit hyperactivity disorder.

93 der, schizophrenia, Alzheimer's disease, and attention deficit hyperactivity disorder.

94 hostimulants, including the calming ones, in attention deficit hyperactivity disorder.

95 sociations with nonatopic conditions such as attention deficit hyperactivity disorder.

96 ce use disorders, pathological gambling, and attention deficit hyperactivity disorder.

97 ariability changes between schizophrenia and attention deficit hyperactivity disorder/autism.

98 he proportion who were clinically at risk of attention deficit hyperactivity disorders after Bonferro

99 ndings are mixed on the relationship between attention-deficit hyperactivity disorder (ADHD) and youn

100 Children with ASD or attention-deficit hyperactivity disorder (ADHD) delivere

101 ral studies have questioned the stability of attention-deficit hyperactivity disorder (ADHD) from chi

102 Attention-deficit hyperactivity disorder (ADHD) is a com

103 Attention-deficit hyperactivity disorder (ADHD) is a neu

104 Attention-deficit hyperactivity disorder (ADHD) is a neu

105 Attention-deficit hyperactivity disorder (ADHD) is a pre

106 Attention-deficit hyperactivity disorder (ADHD) is estim

107 Although attention-deficit hyperactivity disorder (ADHD) is highl

108 For many years, attention-deficit hyperactivity disorder (ADHD) was thou

109 Developmental disabilities, including attention-deficit hyperactivity disorder (ADHD), intelle

110 Attention-deficit hyperactivity disorder (ADHD), one of

111 tine, drugs widely used for the treatment of attention-deficit hyperactivity disorder (ADHD), suppres

112 n two male siblings who share a diagnosis of attention-deficit hyperactivity disorder (ADHD), with ot

113 osed with autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD).

114 lising symptoms, externalising symptoms, and attention-deficit hyperactivity disorder (ADHD).

115 a consistent positive association of AE with attention-deficit hyperactivity disorder (ADHD).

116 Brain Imaging Data Exchange (ABIDE) and the Attention-Deficit Hyperactivity Disorder (ADHD-200) data

117 ic associations between the Pro33 allele and attention-deficit hyperactivity disorder and ASDs.

118 ole in neuropsychiatric disorders, including attention-deficit hyperactivity disorder and drug addict

119 orders, including schizophrenia, depression, attention-deficit hyperactivity disorder and substance a

120 dividuals with major depressive disorder and attention-deficit hyperactivity disorder from their cont

121 associations of smoking with drug and AUDs, attention-deficit hyperactivity disorder, bipolar disord

122 evelopmental disabilities, including autism, attention-deficit hyperactivity disorder, dyslexia, and

123 its underlying psychiatric disorders such as attention-deficit hyperactivity disorder.

124 lopmental disorders, particularly autism and attention-deficit hyperactivity disorder.

125 al-reported symptoms of depression, anxiety, attention/deficit hyperactivity disorder (ADHD), opposit

126 risk of bipolar disorder, schizophrenia and attention deficit-hyperactivity disorder.

127 elations were found between extraversion and attention-deficit-hyperactivity disorder (ADHD) and betw

128 ance) that may be differentially impaired in attention-deficit/ hyperactivity disorder (ADHD).

129 gnaling in humans associated with addiction, attention-deficit/ hyperactivity disorder, schizophrenia

130 mental exposure to PBDEs and intelligence or Attention Deficit/Hyperactivity Disorder (ADHD) and atte

131 gression is widely observed in children with attention deficit/hyperactivity disorder (ADHD) and has

132 ental report of learning disability (LD) and attention deficit/hyperactivity disorder (ADHD) in child

133 renatal exposure to PFASs is associated with attention deficit/hyperactivity disorder (ADHD) or child

134 features, including intellectual disability, attention deficit/hyperactivity disorder (ADHD), and aut

135 um PCB levels in infancy are associated with attention deficit/hyperactivity disorder (ADHD)-related

136 with preexisting attention problems, such as attention deficit/hyperactivity disorder (ADHD).

137 cuits may contribute to the core symptoms of Attention Deficit/Hyperactivity Disorder (ADHD).

138 d 3.3-fold (95% CI: 1.4, 7.7) higher odds of attention deficit/hyperactivity disorder problems compar

139 opmental disorders, including schizophrenia, attention deficit/hyperactivity disorder, and autism spe

140 neurologic disorders in offspring, including attention deficit/hyperactivity disorder, autism, and sc

141 nxiety disorders, autism spectrum disorders, attention deficit/hyperactivity disorder, severe learnin

142 several neuropsychiatric diseases, including attention deficit/hyperactivity disorder.

143 renia, bipolar disorder, autism, anxiety and attention deficit/hyperactivity disorder.

144 [0.2%]; adjusted RR, 4.3; 95% CI, 2.3-8.2), attention-deficit/hyperactivity disorder (189 cases [5.3

145 ar bipolar disorder (94.2 [1.69]; P = .004), attention-deficit/hyperactivity disorder (96.3 [0.91]; P

146 ofiles in autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) - preval

147 Attention-deficit/hyperactivity disorder (ADHD) affects

148 Attention-deficit/hyperactivity disorder (ADHD) and anxi

149 Attention-deficit/hyperactivity disorder (ADHD) and bipo

150 compared and contrasted with trajectories in attention-deficit/hyperactivity disorder (ADHD) and chil

151 dication has long been effective in treating attention-deficit/hyperactivity disorder (ADHD) and is c

152 Patients with attention-deficit/hyperactivity disorder (ADHD) and obse

153 lphenidate (MPH) is used clinically to treat attention-deficit/hyperactivity disorder (ADHD) and off-

154 Patients with attention-deficit/hyperactivity disorder (ADHD) are at a

155 Individuals with attention-deficit/hyperactivity disorder (ADHD) are at g

156 Cigarette smoking and attention-deficit/hyperactivity disorder (ADHD) are high

157 earch has demonstrated that individuals with attention-deficit/hyperactivity disorder (ADHD) are more

158 sses underlying persistence and remission of attention-deficit/hyperactivity disorder (ADHD) are poor

159 Epilepsy and attention-deficit/hyperactivity disorder (ADHD) are stro

160 Attention-deficit/hyperactivity disorder (ADHD) can be v

161 Attention-deficit/hyperactivity disorder (ADHD) diagnosi

162 gical and hemodynamic activity is altered in attention-deficit/hyperactivity disorder (ADHD) during t

163 Adults with attention-deficit/hyperactivity disorder (ADHD) exhibit

164 Autism spectrum disorders (ASD) and attention-deficit/hyperactivity disorder (ADHD) frequent

165 Attention-deficit/hyperactivity disorder (ADHD) has an u

166 Attention-deficit/hyperactivity disorder (ADHD) has been

167 Attention-deficit/hyperactivity disorder (ADHD) has been

168 Children and adolescents with attention-deficit/hyperactivity disorder (ADHD) have an

169 Neuroimaging studies of attention-deficit/hyperactivity disorder (ADHD) have mos

170 ic resonance imaging (fMRI) studies of adult attention-deficit/hyperactivity disorder (ADHD) have rev

171 Previous neuroimaging investigations in attention-deficit/hyperactivity disorder (ADHD) have sep

172 volumetric differences were associated with attention-deficit/hyperactivity disorder (ADHD) in a rec

173 ys been a key criterion for the diagnosis of attention-deficit/hyperactivity disorder (ADHD) in adult

174 Stimulant medications used to treat attention-deficit/hyperactivity disorder (ADHD) increase

175 Importance: Attention-deficit/hyperactivity disorder (ADHD) is a her

176 Attention-deficit/hyperactivity disorder (ADHD) is a her

177 Attention-deficit/hyperactivity disorder (ADHD) is a her

178 Attention-deficit/hyperactivity disorder (ADHD) is a hig

179 Attention-deficit/hyperactivity disorder (ADHD) is a neu

180 Attention-deficit/hyperactivity disorder (ADHD) is a neu

181 Attention-deficit/hyperactivity disorder (ADHD) is a pre

182 Attention-deficit/hyperactivity disorder (ADHD) is among

183 Attention-deficit/hyperactivity disorder (ADHD) is assoc

184 Studies have shown that attention-deficit/hyperactivity disorder (ADHD) is assoc

185 Attention-deficit/hyperactivity disorder (ADHD) is assoc

186 Attention-deficit/hyperactivity disorder (ADHD) is assoc

187 Recognition that adult attention-deficit/hyperactivity disorder (ADHD) is commo

188 Attention-deficit/hyperactivity disorder (ADHD) is conce

189 Although attention-deficit/hyperactivity disorder (ADHD) is highl

190 Previous research indicates that attention-deficit/hyperactivity disorder (ADHD) is highl

191 Attention-deficit/hyperactivity disorder (ADHD) is incre

192 p between autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) is incre

193 Attention-deficit/hyperactivity disorder (ADHD) is now r

194 Adult attention-deficit/hyperactivity disorder (ADHD) is preva

195 Attention-deficit/hyperactivity disorder (ADHD) is the m

196 Attention-deficit/hyperactivity disorder (ADHD) often pe

197 Attention-deficit/hyperactivity disorder (ADHD) shows su

198 A neurobiological-based classification of attention-deficit/hyperactivity disorder (ADHD) subtypes

199 based on network strength at rest predicted attention-deficit/hyperactivity disorder (ADHD) symptoms

200 Attention-deficit/hyperactivity disorder (ADHD) symptoms

201 ssociated with a categorical ASD diagnosis); attention-deficit/hyperactivity disorder (ADHD) traits (

202 when obsessive-compulsive disorder (OCD) and attention-deficit/hyperactivity disorder (ADHD) were exc

203 elating maternal smoking during pregnancy to attention-deficit/hyperactivity disorder (ADHD) without

204 modeling complex brain disorders, including attention-deficit/hyperactivity disorder (ADHD), aggress

205 to investigate the genetic susceptibility of Attention-Deficit/Hyperactivity Disorder (ADHD), but wit

206 phenidate hydrochloride for the treatment of attention-deficit/hyperactivity disorder (ADHD), little

207 ivity, a multifaceted behavioral hallmark of attention-deficit/hyperactivity disorder (ADHD), strongl

208 er to better understand the underpinnings of attention-deficit/hyperactivity disorder (ADHD), we targ

209 Here we focus on attention-deficit/hyperactivity disorder (ADHD), which i

210 Genetic factors predispose individuals to attention-deficit/hyperactivity disorder (ADHD).

211 lia, and the cerebellum has been reported in attention-deficit/hyperactivity disorder (ADHD).

212 ted in the promoter region of this gene with attention-deficit/hyperactivity disorder (ADHD).

213 sociation between atopic dermatitis (AD) and attention-deficit/hyperactivity disorder (ADHD).

214 stimulant commonly used for the treatment of attention-deficit/hyperactivity disorder (ADHD).

215 are at markedly elevated risk of developing attention-deficit/hyperactivity disorder (ADHD).

216 enidate, is the most effective treatment for attention-deficit/hyperactivity disorder (ADHD).

217 s may involve the pathogenesis of autism and attention-deficit/hyperactivity disorder (ADHD).

218 xisting psychiatric categories for childhood attention-deficit/hyperactivity disorder (ADHD).

219 holine receptors improves cognition in adult attention-deficit/hyperactivity disorder (ADHD).

220 ity, few risk genes have been identified for attention-deficit/hyperactivity disorder (ADHD).

221 ion, the dysfunction of which is a factor in attention-deficit/hyperactivity disorder (ADHD).

222 lfated form (DHEA-S), and characteristics of attention-deficit/hyperactivity disorder (ADHD).

223 chiatric disorders and could be relevant for attention-deficit/hyperactivity disorder (ADHD).

224 riants with long repeats have been linked to attention-deficit/hyperactivity disorder (ADHD); however

225 The hD4.7 variant has been linked to attention-deficit/hyperactivity disorder (ADHD); however

226 s or harms for children and adolescents with attention-deficit/hyperactivity disorder (ADHD)?

227 disorder (HR, 0.83 [95% CI, 0.62-1.13]), or attention-deficit/hyperactivity disorder (HR, 0.99 [95%

228 h schizophrenia (N=3540), autism (N=16 146), attention-deficit/hyperactivity disorder (N=18 726) and

229 Individuals with attention-deficit/hyperactivity disorder (probands) had

230 Attention-deficit/hyperactivity disorder according to DS

231 Aberrant DAT function is implicated in attention-deficit/hyperactivity disorder and autism spec

232 disorders, including infantile parkinsonism, attention-deficit/hyperactivity disorder and autism spec

233 s characterized by high impulsivity, such as attention-deficit/hyperactivity disorder and bipolar dis

234 Some conditions, such as attention-deficit/hyperactivity disorder and inpatient w

235 opment of novel pharmacologic treatments for attention-deficit/hyperactivity disorder and other condi

236 r across sex, after excluding relatives with attention-deficit/hyperactivity disorder and probands wi

237 l relevance to the etiology and treatment of attention-deficit/hyperactivity disorder and related dis

238 hiatric disorders listed in DSM-5, including attention-deficit/hyperactivity disorder and substance u

239 e risk of suicidal behavior in patients with attention-deficit/hyperactivity disorder and suggests th

240 rgent results were obtained for the level of attention-deficit/hyperactivity disorder and the influen

241 disorder and suggests that individuals with attention-deficit/hyperactivity disorder and their famil

242 Attention-deficit/hyperactivity disorder and well-dental

243 ed vs 5.46% of unexposed were diagnosed with attention-deficit/hyperactivity disorder by age 15 years

244 sits in 2007-2010 but represented 55.9% when attention-deficit/hyperactivity disorder codes were excl

245 e drugs, antihypertensive drugs, sleep aids, attention-deficit/hyperactivity disorder drugs, and anti

246 for the treatment of insomnia [sleep aids], attention-deficit/hyperactivity disorder drugs, antidepr

247 The adult form of attention-deficit/hyperactivity disorder has a prevalenc

248 hazard ratio [HR], 2.02 [95% CI, 1.80-2.26]; attention-deficit/hyperactivity disorder HR, 2.21 [95% C

249 disorders such as schizophrenia, autism, and attention-deficit/hyperactivity disorder in humans.

250 al diagnosis of autism spectrum disorder and attention-deficit/hyperactivity disorder in offspring.

251 tipsychotics, the most common diagnoses were attention-deficit/hyperactivity disorder in younger chil

252 Attention-deficit/hyperactivity disorder is associated w

253 Attention-deficit/hyperactivity disorder is often treate

254 While there was no association with comorbid attention-deficit/hyperactivity disorder or IQ, age rang

255 Main Outcomes and Measures: Attention-deficit/hyperactivity disorder symptom traject

256 tion (outlier magnitude) relates to specific attention-deficit/hyperactivity disorder symptoms (hyper

257 externalizing behavioral problems, including attention-deficit/hyperactivity disorder symptoms and co

258 ediate factors (child executive function and attention-deficit/hyperactivity disorder symptoms) and c

259 ants contributes to slower processing speed, attention-deficit/hyperactivity disorder symptoms, and e

260 Attention-deficit/hyperactivity disorder was not signifi

261 s between ICN dysmaturation and diagnosis of attention-deficit/hyperactivity disorder were identified

262 sorder, bipolar disorder, schizophrenia, and attention-deficit/hyperactivity disorder).

263 pes of care and inpatient well-newborn care, attention-deficit/hyperactivity disorder, and asthma amo

264 ial behavior, posttraumatic stress disorder, attention-deficit/hyperactivity disorder, and conduct pr

265 ral psychiatric diseases, such as addiction, attention-deficit/hyperactivity disorder, and schizophre

266 al psychiatric disorders, such as addiction, attention-deficit/hyperactivity disorder, and schizophre

267 rodevelopmental disorders, including autism, attention-deficit/hyperactivity disorder, and schizophre

268 ts with a psychiatric diagnosis of interest (attention-deficit/hyperactivity disorder, autism spectru

269 For social anxiety disorder and attention-deficit/hyperactivity disorder, complete media

270 between them and schizophrenia, depression, attention-deficit/hyperactivity disorder, eating disorde

271 nidate, a common and effective treatment for attention-deficit/hyperactivity disorder, in healthy adu

272 Psychiatric (autism, attention-deficit/hyperactivity disorder, psychosis, bip

273 disorders (intellectual disability, autism, attention-deficit/hyperactivity disorder, schizophrenia,

274 the genetic signature of DD overlapped with attention-deficit/hyperactivity disorder, schizophrenia,

275 of suicidal behavior among individuals with attention-deficit/hyperactivity disorder, the developmen

276 olar disorder, major depressive disorder, or attention-deficit/hyperactivity disorder.

277 ntinuous Performance Test and diagnosis with attention-deficit/hyperactivity disorder.

278 on models or after the exclusion of comorbid attention-deficit/hyperactivity disorder.

279 nts are highly effective in the treatment of attention-deficit/hyperactivity disorder.

280 istent with previous findings in adults with attention-deficit/hyperactivity disorder.

281 psychiatric condition or substance abuse and attention-deficit/hyperactivity disorder.

282 radrenergic reuptake inhibitor used to treat attention-deficit/hyperactivity disorder.

283 cluding schizophrenia, bipolar disorder, and attention-deficit/hyperactivity disorder.

284 estational age, autism spectrum disorder, or attention-deficit/hyperactivity disorder.

285 analysis, of whom 25 (4.8%) met criteria for attention-deficit/hyperactivity disorder.

286 xiety, disruptive mood dysregulation, and/or attention-deficit/hyperactivity disorders and 22 healthy

287 and posttraumatic stress) and externalizing (attention-deficit/hyperactivity, intermittent explosive,

288 d Interview for Prodromal Syndromes, and for attention-deficit/hyperactivity, substance-related, and

289 Attention deficits in Alzheimer's disease can exacerbate

290 severity of memory, executive function, and attention deficits in children with FASDs.

291 ecently reported that spatial and nonspatial attention deficits in stroke patients with hemispatial n

292 Improvement of attention deficits, independent of initial severity, was

293 e effect of oxytocin on reversing non-social attention deficits is a particularly novel finding, and

294 Attention deficits may present dysfunctions in any one o

295 Attention deficit recovery was mostly complete by 3 mont

296 f reality, disruption of working memory, and attention deficits that characterize these disorders.

297 Alzheimer's disease is accompanied by attention deficits that exacerbate its other cognitive s

298 Summary measures for motor and attention deficits were identified through principal com

299 Attention deficits were significantly more correlated wi

300 network normalization." METHODS: We measured attention deficits with a neuropsychological battery and